Abstract Body

Background

Endogenous retroviruses (ERVs) have a potential regulatory and pathogenic role in cancer. Antiretrovirals have been reported to influence HERV activity, but little is known about their interactions with classical chemotherapeutics. We investigated whether antiretrovirals Dolutegravir (DTG) and Doravirine (DOR) alter HERV-K expression and cytotoxic responses to Doxorubicin (D) and Vincristine (V) in lymphoma cell lines (BJAB & L428).

Methods

HERV-K env & gag expression was quantified with RT-PCR. Expression was normalized to β-actin & GADPH. A change of >10 fold was considered significant. IC50 values for DTG, DOR, D & V were determined with MTT. Chemotherapeutics were administered at IC50 & antiretrovirals at IC20. Cell viability was measured with JuLi Br at the 2nd & 24th hours. Cells were grouped as early apoptosis (EA), late apoptosis (LA) and necrosis (Nec) with Annexin V staining.

Results

HERV-K gag expression was not detected; all analyses were continued with HERV-env. IC50 levels of antiretrovirals DTG 3.733 mM (L428), 25.31mM (BJAB); DOR 0.642 mM (L428), 0.778 mM (BJAB). Chemotherapeutic IC50 for D 0.552 mM (L428), 0.496 mM (BJAB); for V 0.22 mM (L428) & 0.237 mM (BJAB). The IC20 of antiretrovirals: for DTG 2.78 mM (L428), for DOR 0.52 mM (L428); DTG 15.4 mM (BJAB), & DOR 0.45 mM (BJAB). Combination groups enhanced HERV-env expression relative to single drugs. Some groups did not reach an increase of 10 times and therefore were not significant. Exposure to D induced the highest increase in HERV-K expression (400-3000 times). Interestingly, V+DTG increased env expression of 50 times in L428 cells, more than either agent alone (Table 1). JuLi Br assay showed a progressive loss of viable cells between the 2nd & 24th hours. The highest loss was in DOR+D group (%64); the lowest was V+DTG (9%) in L428 cells, less than either agent separately (Table 1). In the Annexin V assay, the L428 groups containing D almost exclusively resulted in necrosis, and the L428 V-DTG group showed an increase in late apoptotic cells compared to V or DTG alone (Table 2).

Conclusions

Chemotherapeutics, especially D, strongly up-regulate HERV-K env in lymphoma cells, and antiretrovirals further modulate this response. The observed links between drug-induced stress, endogenous retroviral activation, and cell death mechanisms highlight a potential role for HERV-K in therapy response and resistance. These findings support further investigation of HERV-K as both a biomarker and a therapeutic target in lymphoma.

Table or Figure